MicroRNA-34a activation in tuberous sclerosis complex during early brain development may lead to impaired corticogenesis

A. Korotkov; N.S. Sim; M.J. Luinenburg; J.J. Anink; J. van Scheppingen; T.S. Zimmer; A. Bongaarts; D.W.M. Broekaart; C. Mijnsbergen; F.E. Jansen; W. Van Hecke; W.G.M. Spliet; P.C. van Rijen; M. Feucht; J.A. Hainfellner; P. Kršek; J. Zamecnik; P.B. Crino; K. Kotulska; L. Lagae; A.C. Jansen; D.J. Kwiatkowski; S. Jozwiak; P. Curatolo; A. Mühlebner; J.H. Lee; J.D. Mills; E.A. van Vliet; E. Aronica

doi:https://doi.org/10.1111/nan.12717

MicroRNA-34a activation in tuberous sclerosis complex during early brain development may lead to impaired corticogenesis

A. Korotkov, N.S. Sim, M.J. Luinenburg, J.J. Anink, J. van Scheppingen, T.S. Zimmer, A. Bongaarts, D.W.M. Broekaart, C. Mijnsbergen, F.E. Jansen, W. Van Hecke, W.G.M. Spliet, P.C. van Rijen, M. Feucht, J.A. Hainfellner, P. Kršek, J. Zamecnik, P.B. Crino, K. Kotulska, L. LagaeA.C. Jansen, D.J. Kwiatkowski, S. Jozwiak, P. Curatolo, A. Mühlebner, J.H. Lee, J.D. Mills, E.A. van Vliet, E. Aronica

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

Abstract

AIMS: Tuberous sclerosis complex (TSC) is a genetic disorder associated with dysregulation of the mechanistic target of rapamycin complex 1 (mTORC1) signalling pathway. Neurodevelopmental disorders, frequently present in TSC, are linked to cortical tubers in the brain. We previously reported microRNA-34a (miR-34a) among the most upregulated miRs in tubers. Here, we characterised miR-34a expression in tubers with the focus on the early brain development and assessed the regulation of mTORC1 pathway and corticogenesis by miR-34a.

METHODS: We analysed the expression of miR-34a in resected cortical tubers (n = 37) compared with autopsy-derived control tissue (n = 27). The effect of miR-34a overexpression on corticogenesis was assessed in mice at E18. The regulation of the mTORC1 pathway and the expression of the bioinformatically predicted target genes were assessed in primary astrocyte cultures from three patients with TSC and in SH-SY5Y cells following miR-34a transfection.

RESULTS: The peak of miR-34a overexpression in tubers was observed during infancy, concomitant with the presence of pathological markers, particularly in giant cells and dysmorphic neurons. miR-34a was also strongly expressed in foetal TSC cortex. Overexpression of miR-34a in mouse embryos decreased the percentage of cells migrated to the cortical plate. The transfection of miR-34a mimic in TSC astrocytes negatively regulated mTORC1 and decreased the expression of the target genes RAS related (RRAS) and NOTCH1.

CONCLUSIONS: MicroRNA-34a is most highly overexpressed in tubers during foetal and early postnatal brain development. miR-34a can negatively regulate mTORC1; however, it may also contribute to abnormal corticogenesis in TSC.

Original language	English
Pages (from-to)	796-811
Number of pages	16
Journal	Neuropathology and applied neurobiology
Volume	47
Issue number	6
Early online date	2021
DOIs	https://doi.org/10.1111/nan.12717
Publication status	Published - Oct 2021

Keywords

TSC
mechanistic target of rapamycin
miRNA
migration
neurodevelopmental disorder

Access to Document

https://doi.org/10.1111/nan.12717Licence: CC BY-NC-ND

https://pure.uva.nl/ws/files/64034569/nan.12717.pdfLicence: CC BY-NC-ND

Cite this

Korotkov, A., Sim, N. S., Luinenburg, M. J., Anink, J. J., van Scheppingen, J., Zimmer, T. S., Bongaarts, A., Broekaart, D. W. M., Mijnsbergen, C., Jansen, F. E., Van Hecke, W., Spliet, W. G. M., van Rijen, P. C., Feucht, M., Hainfellner, J. A., Kršek, P., Zamecnik, J., Crino, P. B., Kotulska, K., ... Aronica, E. (2021). MicroRNA-34a activation in tuberous sclerosis complex during early brain development may lead to impaired corticogenesis. Neuropathology and applied neurobiology, 47(6), 796-811. https://doi.org/10.1111/nan.12717

@article{780cf1a2c5ac411eabb35f9501b9e251,

title = "MicroRNA-34a activation in tuberous sclerosis complex during early brain development may lead to impaired corticogenesis",

abstract = "AIMS: Tuberous sclerosis complex (TSC) is a genetic disorder associated with dysregulation of the mechanistic target of rapamycin complex 1 (mTORC1) signalling pathway. Neurodevelopmental disorders, frequently present in TSC, are linked to cortical tubers in the brain. We previously reported microRNA-34a (miR-34a) among the most upregulated miRs in tubers. Here, we characterised miR-34a expression in tubers with the focus on the early brain development and assessed the regulation of mTORC1 pathway and corticogenesis by miR-34a.METHODS: We analysed the expression of miR-34a in resected cortical tubers (n = 37) compared with autopsy-derived control tissue (n = 27). The effect of miR-34a overexpression on corticogenesis was assessed in mice at E18. The regulation of the mTORC1 pathway and the expression of the bioinformatically predicted target genes were assessed in primary astrocyte cultures from three patients with TSC and in SH-SY5Y cells following miR-34a transfection.RESULTS: The peak of miR-34a overexpression in tubers was observed during infancy, concomitant with the presence of pathological markers, particularly in giant cells and dysmorphic neurons. miR-34a was also strongly expressed in foetal TSC cortex. Overexpression of miR-34a in mouse embryos decreased the percentage of cells migrated to the cortical plate. The transfection of miR-34a mimic in TSC astrocytes negatively regulated mTORC1 and decreased the expression of the target genes RAS related (RRAS) and NOTCH1.CONCLUSIONS: MicroRNA-34a is most highly overexpressed in tubers during foetal and early postnatal brain development. miR-34a can negatively regulate mTORC1; however, it may also contribute to abnormal corticogenesis in TSC.",

keywords = "TSC, mechanistic target of rapamycin, miRNA, migration, neurodevelopmental disorder",

author = "A. Korotkov and N.S. Sim and M.J. Luinenburg and J.J. Anink and {van Scheppingen}, J. and T.S. Zimmer and A. Bongaarts and D.W.M. Broekaart and C. Mijnsbergen and F.E. Jansen and {Van Hecke}, W. and W.G.M. Spliet and {van Rijen}, P.C. and M. Feucht and J.A. Hainfellner and P. Kr{\v s}ek and J. Zamecnik and P.B. Crino and K. Kotulska and L. Lagae and A.C. Jansen and D.J. Kwiatkowski and S. Jozwiak and P. Curatolo and A. M{\"u}hlebner and J.H. Lee and J.D. Mills and {van Vliet}, E.A. and E. Aronica",

note = "Funding Information: The research leading to these results has received funding from the European Union's Seventh Framework Program (FP7/2007-2013) under grant agreement 602102 (EPITARGET; EAvV, EA) and 602391 (EPISTOP; EA, MF, PK, KK, LL, ACJ, DJK, SJ, PC, AM, JDM, AM, JvS, FEJ), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement 642881 (ECMED; AK, EA, EAvV) and 722053 (EU-GliaPhD; TSZ, EA, EAvV), as well as 952455 (EpiEpiNet, EA, EAvV, JM) and the Dutch Epilepsy Foundation, project number 20-02 (AM, MJL). The research leading to these results has received funding from the European Union's Seventh Framework Program (FP7/2007-2013) under grant agreement 602102 (EPITARGET; EAvV, EA) and 602391 (EPISTOP; EA, MF, PK, KK, LL, ACJ, DJK, SJ, PC, AM, JDM, AM, JvS, FEJ), the European Union?s Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement no. 642881 (ECMED; AK, EA, EAvV) and no. 722053 (EU-GliaPhD; TSZ, EA, EAvV), as well as no. 952455 (EpiEpiNet, EA, EAvV, JM) and the Dutch Epilepsy Foundation, project number 20-02 (AM,MJL). Funding Information: no. 952455 (EpiEpiNet, EA, EAvV, JM) and the Dutch Epilepsy Foundation, project number 20‐02 (AM,MJL). Funding Information: The research leading to these results has received funding from the European Union's Seventh Framework Program (FP7/2007‐2013) under grant agreement 602102 (EPITARGET; EAvV, EA) and 602391 (EPISTOP; EA, MF, PK, KK, LL, ACJ, DJK, SJ, PC, AM, JDM, AM, JvS, FEJ), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska‐Curie grant agreement 642881 (ECMED; AK, EA, EAvV) and 722053 (EU‐GliaPhD; TSZ, EA, EAvV), as well as 952455 (EpiEpiNet, EA, EAvV, JM) and the Dutch Epilepsy Foundation, project number 20‐02 (AM, MJL). Funding Information: The research leading to these results has received funding from the European Union's Seventh Publisher Copyright: {\textcopyright} 2021 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = oct,

doi = "https://doi.org/10.1111/nan.12717",

language = "English",

volume = "47",

pages = "796--811",

journal = "Neuropathology and applied neurobiology",

issn = "0305-1846",

publisher = "Wiley-Blackwell",

number = "6",

}

Korotkov, A, Sim, NS, Luinenburg, MJ , Anink, JJ, van Scheppingen, J, Zimmer, TS, Bongaarts, A, Broekaart, DWM, Mijnsbergen, C, Jansen, FE, Van Hecke, W, Spliet, WGM, van Rijen, PC, Feucht, M, Hainfellner, JA, Kršek, P, Zamecnik, J, Crino, PB, Kotulska, K, Lagae, L, Jansen, AC, Kwiatkowski, DJ, Jozwiak, S, Curatolo, P, Mühlebner, A, Lee, JH, Mills, JD, van Vliet, EA & Aronica, E 2021, 'MicroRNA-34a activation in tuberous sclerosis complex during early brain development may lead to impaired corticogenesis', Neuropathology and applied neurobiology, vol. 47, no. 6, pp. 796-811. https://doi.org/10.1111/nan.12717

TY - JOUR

T1 - MicroRNA-34a activation in tuberous sclerosis complex during early brain development may lead to impaired corticogenesis

AU - Korotkov, A.

AU - Sim, N.S.

AU - Luinenburg, M.J.

AU - Anink, J.J.

AU - van Scheppingen, J.

AU - Zimmer, T.S.

AU - Bongaarts, A.

AU - Broekaart, D.W.M.

AU - Mijnsbergen, C.

AU - Jansen, F.E.

AU - Van Hecke, W.

AU - Spliet, W.G.M.

AU - van Rijen, P.C.

AU - Feucht, M.

AU - Hainfellner, J.A.

AU - Kršek, P.

AU - Zamecnik, J.

AU - Crino, P.B.

AU - Kotulska, K.

AU - Lagae, L.

AU - Jansen, A.C.

AU - Kwiatkowski, D.J.

AU - Jozwiak, S.

AU - Curatolo, P.

AU - Mühlebner, A.

AU - Lee, J.H.

AU - Mills, J.D.

AU - van Vliet, E.A.

AU - Aronica, E.

N1 - Funding Information: The research leading to these results has received funding from the European Union's Seventh Framework Program (FP7/2007-2013) under grant agreement 602102 (EPITARGET; EAvV, EA) and 602391 (EPISTOP; EA, MF, PK, KK, LL, ACJ, DJK, SJ, PC, AM, JDM, AM, JvS, FEJ), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement 642881 (ECMED; AK, EA, EAvV) and 722053 (EU-GliaPhD; TSZ, EA, EAvV), as well as 952455 (EpiEpiNet, EA, EAvV, JM) and the Dutch Epilepsy Foundation, project number 20-02 (AM, MJL). The research leading to these results has received funding from the European Union's Seventh Framework Program (FP7/2007-2013) under grant agreement 602102 (EPITARGET; EAvV, EA) and 602391 (EPISTOP; EA, MF, PK, KK, LL, ACJ, DJK, SJ, PC, AM, JDM, AM, JvS, FEJ), the European Union?s Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement no. 642881 (ECMED; AK, EA, EAvV) and no. 722053 (EU-GliaPhD; TSZ, EA, EAvV), as well as no. 952455 (EpiEpiNet, EA, EAvV, JM) and the Dutch Epilepsy Foundation, project number 20-02 (AM,MJL). Funding Information: no. 952455 (EpiEpiNet, EA, EAvV, JM) and the Dutch Epilepsy Foundation, project number 20‐02 (AM,MJL). Funding Information: The research leading to these results has received funding from the European Union's Seventh Framework Program (FP7/2007‐2013) under grant agreement 602102 (EPITARGET; EAvV, EA) and 602391 (EPISTOP; EA, MF, PK, KK, LL, ACJ, DJK, SJ, PC, AM, JDM, AM, JvS, FEJ), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska‐Curie grant agreement 642881 (ECMED; AK, EA, EAvV) and 722053 (EU‐GliaPhD; TSZ, EA, EAvV), as well as 952455 (EpiEpiNet, EA, EAvV, JM) and the Dutch Epilepsy Foundation, project number 20‐02 (AM, MJL). Funding Information: The research leading to these results has received funding from the European Union's Seventh Publisher Copyright: © 2021 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/10

Y1 - 2021/10

N2 - AIMS: Tuberous sclerosis complex (TSC) is a genetic disorder associated with dysregulation of the mechanistic target of rapamycin complex 1 (mTORC1) signalling pathway. Neurodevelopmental disorders, frequently present in TSC, are linked to cortical tubers in the brain. We previously reported microRNA-34a (miR-34a) among the most upregulated miRs in tubers. Here, we characterised miR-34a expression in tubers with the focus on the early brain development and assessed the regulation of mTORC1 pathway and corticogenesis by miR-34a.METHODS: We analysed the expression of miR-34a in resected cortical tubers (n = 37) compared with autopsy-derived control tissue (n = 27). The effect of miR-34a overexpression on corticogenesis was assessed in mice at E18. The regulation of the mTORC1 pathway and the expression of the bioinformatically predicted target genes were assessed in primary astrocyte cultures from three patients with TSC and in SH-SY5Y cells following miR-34a transfection.RESULTS: The peak of miR-34a overexpression in tubers was observed during infancy, concomitant with the presence of pathological markers, particularly in giant cells and dysmorphic neurons. miR-34a was also strongly expressed in foetal TSC cortex. Overexpression of miR-34a in mouse embryos decreased the percentage of cells migrated to the cortical plate. The transfection of miR-34a mimic in TSC astrocytes negatively regulated mTORC1 and decreased the expression of the target genes RAS related (RRAS) and NOTCH1.CONCLUSIONS: MicroRNA-34a is most highly overexpressed in tubers during foetal and early postnatal brain development. miR-34a can negatively regulate mTORC1; however, it may also contribute to abnormal corticogenesis in TSC.

AB - AIMS: Tuberous sclerosis complex (TSC) is a genetic disorder associated with dysregulation of the mechanistic target of rapamycin complex 1 (mTORC1) signalling pathway. Neurodevelopmental disorders, frequently present in TSC, are linked to cortical tubers in the brain. We previously reported microRNA-34a (miR-34a) among the most upregulated miRs in tubers. Here, we characterised miR-34a expression in tubers with the focus on the early brain development and assessed the regulation of mTORC1 pathway and corticogenesis by miR-34a.METHODS: We analysed the expression of miR-34a in resected cortical tubers (n = 37) compared with autopsy-derived control tissue (n = 27). The effect of miR-34a overexpression on corticogenesis was assessed in mice at E18. The regulation of the mTORC1 pathway and the expression of the bioinformatically predicted target genes were assessed in primary astrocyte cultures from three patients with TSC and in SH-SY5Y cells following miR-34a transfection.RESULTS: The peak of miR-34a overexpression in tubers was observed during infancy, concomitant with the presence of pathological markers, particularly in giant cells and dysmorphic neurons. miR-34a was also strongly expressed in foetal TSC cortex. Overexpression of miR-34a in mouse embryos decreased the percentage of cells migrated to the cortical plate. The transfection of miR-34a mimic in TSC astrocytes negatively regulated mTORC1 and decreased the expression of the target genes RAS related (RRAS) and NOTCH1.CONCLUSIONS: MicroRNA-34a is most highly overexpressed in tubers during foetal and early postnatal brain development. miR-34a can negatively regulate mTORC1; however, it may also contribute to abnormal corticogenesis in TSC.

KW - TSC

KW - mechanistic target of rapamycin

KW - miRNA

KW - migration

KW - neurodevelopmental disorder

UR - http://www.scopus.com/inward/record.url?scp=85107727171&partnerID=8YFLogxK

U2 - https://doi.org/10.1111/nan.12717

DO - https://doi.org/10.1111/nan.12717

M3 - Article

C2 - 33942341

SN - 0305-1846

VL - 47

SP - 796

EP - 811

JO - Neuropathology and applied neurobiology

JF - Neuropathology and applied neurobiology

IS - 6

ER -

MicroRNA-34a activation in tuberous sclerosis complex during early brain development may lead to impaired corticogenesis

Abstract

Keywords

Access to Document

Other files and links

Cite this